Company Update (NASDAQ:AMGN): Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis

[PR Newswire] – THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ — Amgen (AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, . . . → Read More: Company Update (NASDAQ:AMGN): Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fighting drug Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 Second Quarter Financial Results